Fig. 2: Cellular immunogenicity outcomes for adolescents were mostly non-inferior or inconclusive in adolescents in comparison to adults.

a, b Adolescents receiving one dose of BNT162b2 (B; N = 58) and 2 doses of BNT162b2 (BB; N = 56) and c adolescents receiving 2 doses of CoronaVac (CC; N = 60) were tested for IFN-γ⁺ and IL-2⁺ CD4⁺ and CD8⁺ T cells on flow-cytometry-based intracellular cytokine staining assays specific to S (and N and M for CC) for 21 days after dose 1 and 28 days after dose 2. The results of SNM-specific T cell responses were calculated from the sum of responses of the individual S, N and M peptide pools. S-specific IFN-γ⁺CD4⁺, IL-2⁺CD4⁺ and IFN-γ⁺CD8⁺ T cell responses were non-inferior for adolescent BB in comparison to adults (N = 47). For adolescent CC compared to adults (N = 36), SNM-specific IL-2⁺CD4⁺, IFN-γ⁺CD8⁺ and IL-2⁺CD8⁺, N-specific IFN-γ⁺CD4⁺, IL-2⁺CD4⁺, IFN-γ⁺CD8⁺ and IL-2⁺CD8⁺, M-specific IFN-γ⁺CD8⁺ and IL-2⁺CD8⁺ were non-inferior. The remaining cellular immunogenicity outcomes were inconclusive. Dots and error bars show GMR estimates and two-sided 95% CI respectively. GMR geometric mean ratio, CI confidence interval, S spike protein, N nucleocapsid protein, M membrane protein, IFN-γ interferon-γ, IL-2 interleukin-2.